Recent Placements and Client News

Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Andrew Obenshain as Chief Executive Officer (“CEO”) of the Company. Mr. Obenshain will also join the Company’s Board of Directors. He succeeds Frédéric Cren, the Company’s co-founder, who has served as CEO since its inception ...

Avalo Therapeutics, Inc., a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with the appointment of Taylor Boyd to Chief Business Officer.

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform, today announced the appointment of Mauro Avanzi, M.D., Ph.D., as Chief Medical Officer. Dr. Avanzi is a Board-certified hematologist/oncologist, a physician-scientist and an immunologist with more than 15 years of clinical development experience across early and late stages. He will lead Dispatch’s clinical ...

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that Usman “Oz” Azam, M.D., has been appointed President and Chief Executive Officer (CEO) of Cue Biopharma, effective September 29, 2025.

Avalo Therapeutics, Inc., a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit.

Artios Pharma Limited, a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response (“DDR”) in cancer, today announced the appointment of Mike Andriole as Chief Executive Officer (CEO) and Director.

Lyric, a market leading, AI-first healthcare technology company, today announced the appointment of Meera Kataria Atkins, MD, MBA, FACOG as its first-ever Chief Medical Officer. The creation of this executive role signals Lyric’s strategic commitment to embedding deep clinical expertise and proactive medical leadership at the heart of its content development initiatives.

BBOT, a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the appointment of Uneek Mehra as Chief Financial Officer. Mr. Mehra brings more than 28 years of global financial and business leadership experience across the biotechnology and pharmaceutical industries.

Brenig Therapeutics, a clinical-stage biotechnology company pioneering AI-powered small-molecule therapies for neurodegenerative diseases, today announced two key executive appointments. David L. Lucchino has been named President and Chief Executive Officer and will also join the company’s Board of Directors. Tien Dam, M.D., has been appointed Chief Medical Officer to lead clinical development and advance its neurology pipeline.

 Crescent Biopharma, Inc., a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the appointment of Jan Pinkas, Ph.D., as chief scientific officer. Dr. Pinkas brings more than two decades of experience in oncology drug development, leading preclinical and translational research with expertise in multiple modalities, including antibody-drug conjugates (ADCs).

Radiant Biotherapeutics, a biotechnology company committed to advancing and delivering transformative MULTi-specific, multi-Affinity antiBODY (Multabody™) therapeutics for patients with cancer and autoimmune diseases, today announced the appointment of seasoned biotechnology executive Deborah Geraghty, Ph.D., as President and Chief Executive Officer.

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the appointment of Shishir Gadam, Ph.D., as chief technical officer. Dr. Gadam has extensive experience in the biotechnology industry and brings deep expertise and leadership in biologics development and manufacturing to Marea Therapeutics.

Jade Biosciences, Inc., a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Brad Dahms as Chief Financial Officer.

OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today announced the appointment of Dimitry S.A. Nuyten, M.D., Ph.D., as Chief Medical Officer (CMO).

Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), effective immediately.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Simon Read, Ph.D., to the Company’s Board of Directors. Dr. Read is a serial entrepreneur with more than 30 years of biopharmaceutical experience. Dianthus also announced that Lonnie Moulder will transition from the ...

Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately.

Take Command, a leading health benefits technology company and the largest provider of Individual Coverage Health Reimbursement Arrangements (ICHRAs) in the country, announced that Jamie Potecha has been appointed the company’s Chief Operating Officer. Potecha will lead efforts to strengthen the systems and teams that make it easier for employees to navigate and maximize their health benefits.

vTv Therapeutics Inc., a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical industry. This executive appointment comes at an important time for the Company, ...

Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer.

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the appointment of Jason Keyes, as Chief Financial Officer and Executive Vice President. Mr. Keyes has an extensive track record of providing financial and strategic leadership to biopharmaceutical companies of all stages from emerging ...

Seamless Therapeutics today announced the appointment of Alvin Shih, M.D., M.B.A., as an Independent Director to its Board. Dr. Shih is an experienced drug developer and physician with a track record of successfully building and guiding companies focused on multiple therapeutic areas, including rare diseases. Dr Shih’s appointment to their Board will further strengthen the company as it advances its ...

TRexBio, a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced the expansion of its executive leadership team with the appointment of Brandon Hants, MBA, as Chief Financial Officer (CFO). This leadership addition will support TRexBio as the company prepares to initiate its first-in-human clinical trial of TRB-061, a novel TNFR2 agonist for the treatment of ...

Climb Bio, Inc. today announced the appointment of biotech industry veteran Bo Cumbo to its Board of Directors. Mr. Cumbo will assume the role of Compensation Committee Chair.

VectorY Therapeutics, a biotechnology company advancing vectorized antibody therapies for neurodegenerative diseases, today announced the appointment of Olga Uspenskaya-Cadoz, M.D., Ph.D., as Chief Medical Officer (CMO).

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Michael Samar as Chief Financial Officer.

CatalYm today announced the appointment of Scott Clarke as Chief Executive Officer. Mr. Clarke brings over two decades of executive leadership experience in driving company growth, developing products, and shaping and executing transactions in the biopharmaceutical industry. He takes the helm as CatalYm enters a new stage of corporate and clinical development, including the initiation of a broad Phase 2b program ...

Iambic Therapeutics, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, announced that Michael Secora, Ph.D. will be its Chief Corporate Development Officer and Chief Financial Officer. Dr Secora will lead Iambic’s finance and corporate development activities, helping frame its growing pipeline and industry-leading platform to potential partners, investors, and other stakeholders.

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer.

Alessa Therapeutics, a clinical-stage drug development company pioneering an innovative and proprietary localized drug delivery technology for the early treatment of prostate cancer and other diseases, announced today the appointment of Cam Gallagher as President and Chief Executive Officer, effective immediately.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer.

Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced the appointment of Peter Olson, Ph.D. to the role of chief scientific officer. Dr. Olson, who was most recently vice president, research at Mirati Therapeutics, a Bristol Myers Squibb (BMS) company, will join Iambic’s executive leadership team.

Compass Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor.

SynOx Therapeutics Limited, a late clinical-stage biopharmaceutical company developing a novel treatment for CSF-1 related and macrophage-driven disorders, today announced the appointment of Robert Francomano as Chief Commercial Officer (CCO).

Ensoma, a genomic medicines company advancing the future of medicine through precision one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the appointment of Jon Garen as chief corporate development and business officer.

 Jade Biosciences, Inc., a biotechnology company dedicated to developing best-in-class therapies for patients living with autoimmune diseases, today announced the appointment of Tom Frohlich as Chief Executive Officer (CEO). The company also introduced its newly formed Board of Directors, marking a significant step in the company’s growth trajectory.

Apnimed, Inc., a pharmaceutical company focused on discovery, development, and commercialization of first-in-class oral therapies that address the neuromuscular dysfunction of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced the appointment of Ramzi Benamar as Chief Financial Officer.

 Alphina Therapeutics, a biotechnology company developing a best-in-class NAMPT inhibitor for the treatment of a range of solid tumor indications, today announced that it has appointed Nick Galli as chief executive officer and a member of the board of directors. Mr. Galli brings nearly twenty years of private and public pharmaceutical and biotechnology industry experience with a focus on strategy, company building, ...

Pacira BioSciences, Inc., known for its non-opioid pain therapies, announced today the appointment of Shawn Cross as Chief Financial Officer. Cross, who carries over 25 years of experience in the biopharmaceutical sector, will oversee the company’s financial strategy and operations.

Xaira Therapeutics launched in April on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH and Foresite Labs, Xaira launched with more than $1 billion of committed capital from lead investors ARCH Venture Partners and Foresite Capital, joined by F-Prime, NEA, Sequoia Capital, Lux ...

Flywheel.io, the leading end-to-end platform for medical imaging data management and analysis, today announced a leadership transition with Matthew A. Michela joining as Chief Executive Officer. Hooman Hakami, Flywheel’s interim CEO, has joined the Flywheel Board of Directors serving as Chair. Matthew’s leadership and Hooman’s continuity in governance will drive Flywheel’s next phase of growth by helping healthcare and life sciences companies accelerate ...

Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for serious unserved orphan diseases, today announced the appointment of Joshua Grass as Chairperson of the Board. Mr. Grass succeeds Christopher Starr, Ph.D., who will continue to support the company as a scientific and clinical advisor.

Wheeler Bio, an agile and boutique contract development and manufacturing organization (CDMO), today announced the appointment of Patrick Lucy as Chief Executive Officer. Patrick joins Wheeler with more than 32 years of extensive experience in the biotechnology industry. As a seasoned senior executive, he has overseen numerous company milestones and driven significant growth.

Tagworks Pharmaceuticals BV (“Tagworks”), a precision oncology company using its proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors by targeting clinically validated tumor markers that so far have remained out of reach of current therapies, today announced the appointment of Ken Mills as Chief Executive Officer and member of the Board of Directors.

Rectify Pharmaceuticals, Inc., a biotechnology company developing small molecule disease-modifying therapeutics that restore and enhance ABC transporter function, today announced the appointment of Pol Boudes, M.D., as Chief Medical Officer. Dr. Boudes brings over 30 years of experience across clinical research and practice, drug development, regulatory affairs and executive leadership.

Guidehealth, a nationally acclaimed, AI-enabled healthcare services provider, today announced the appointment of two industry leaders to its executive team, naming Roger Ou who will join as Chief Financial Officer and Robert Alterman who joins as Chief Performance Officer.

BioAge Labs, Inc., a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the appointment of Jean-Pierre Garnier, PhD, as Chair of the company’s Board of Directors. Garnier will succeed current Board Chair James Healy, MD, PhD, managing partner of Sofinnova Investments, who will remain on the Board.

4G Clinical, a global leader in randomization and trial supply management (RTSM) and supply forecasting optimization software for the life sciences industry, today announced the appointment of Ronan Brown, PhD as their new Chief Operating Officer. Brown’s addition will further strengthen the executive team in support of 4G’s commitment to operational excellence and innovation.

Cerevance, a leading clinical-stage biopharmaceutical company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, has appointed Dr. Sagar Vaidya, M.D. Ph.D. as Chief Medical Officer. Dr. Vaidya brings a wealth of experience in drug development, clinical research, and medical affairs, with a distinguished track record in advancing therapeutic programs for severe and life-threatening diseases.

Sofinnova Investments, a biopharmaceutical investment firm, announced today the addition of Maha Radhakrishnan, M.D. to the investment team as an Executive Partner. Dr. Radhakrishnan is an accomplished industry executive with over 20 years of experience advancing large strategic portfolios across various therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and ...

enGene, a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), today announced that Ron Cooper has joined the Company as Chief Executive Officer and member of the Board of Directors, effective July 22, 2024. This transition follows a previously announced succession plan for Jason ...

Avalo Therapeutics, Inc. today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting time as we prepare to initiate our Phase 2 LOTUS Trial in patients with hidradenitis suppurativa. Mittie brings to Avalo a strong combination of drug development ...

Latigo Biotherapeutics Inc., a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target pain at its source, today announced the appointment of Nima Farzan, MBA, as chief executive officer (CEO).

Meliora Therapeutics, a machine learning therapeutics company developing novel and transformative cancer drugs, today announced the appointment of Dieter Weinand, former Chairman and CEO of Bayer Pharmaceuticals, as Meliora’s Chairman of the Board, and the appointment of Jean-Jacques Bienaimé, former Chairman and CEO of BioMarin, to Meliora’s Board of Directors as Independent Director.

Aktis Oncology, a clinical stage biotechnology company discovering and developing novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the appointment of Akos Czibere, MD, PhD, as Chief Medical Officer.  With nearly 20 years of experience in drug development for hematologic and solid tumor cancers, Dr. Czibere brings significant clinical and scientific expertise and leadership capabilities ...

 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company today announced the appointment of Dr. Andrew Cavey, as its Chief Executive Officer effective September 1, 2024. ITM’s current CEO, Steffen Schuster, will step up to the company’s Supervisory Board.

Capital Rx, the full-service pharmacy benefit manager (‘PBM’) and pharmacy benefit administrator (‘PBA’) advancing our nation’s electronic healthcare infrastructure to improve drug price visibility and patient outcomes, today announced that Antonio Garcia Cueto has joined the company’s executive leadership team as Chief Financial Officer. He will lead the finance department at Capital Rx, overseeing all matters relating to financial strategy, planning, and reporting, ...

Frazier Healthcare Partners, a leading private equity firm focused exclusively on the healthcare industry, is pleased to announce the addition of an experienced professional to its Center of Excellence: Sanji Fernando, Partner – Data & Artificial Intelligence.

Interesting article on PitchBook about Klein Hersh partners Foresite Capital and Vik Bajaj, who launched their AI drug discovery startup Xaira Therapeutics that Klein Hersh is helping to build out, with $1 billion funding. We’re inspired by the work they’re doing to redefine what’s possible in medicine, and passionate about partnering with other organizations innovating with AI across biotech, pharmaceutical, ...

Congratulations to Klein Hersh client FarmboxRx on being named one of TIME Magazine’s Most Influential Companies 2024. We’re inspired by your mission to inspire self-efficacy and improve the lives of your members through healthy food as medicine. We are proud to partner with you to help your organization grow.

Apogee Therapeutics, Inc., a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Lisa Bollinger, MD, has been appointed to the company’s board of directors.

Unlearn, a leader in artificial intelligence research in medicine, today announced the appointment of Steve Herne as its first Chief Commercial Officer. Herne will spearhead commercial strategies to propel the company’s growth following their successful Series C funding.

United BioSource LLC (UBC), a leading provider of evidence development solutions to the biopharmaceutical industry, today announced the appointment of Anthony Luttenberger as its new Chief Commercial Officer. Anthony brings extensive executive leadership and strategic sales experience, spanning the pharmaceutical product life cycle including late-stage drug development, clinical trials, and product commercialization, to UBC. He is skilled at leveraging actionable insights derived ...

 Seamless Therapeutics today announced the appointments of Albert Seymour, Ph.D., as its new President and Chief Executive Officer and Adam Rosenberg as Independent Chairman of the company’s Board of Directors. Both bring longstanding track records of successfully leading trailblazing biotechnology companies with an emphasis on gene editing and novel technologies. In addition, their combined experience will be instrumental in establishing Seamless ...

BioAge Labs, Inc., a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company’s board of directors.

Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Julie Clauss, MBA, as chief operating officer and Christopher Butler, Ph.D., as senior vice president (SVP), head of Chemistry. Together, these individuals bring more than 40 years of leadership experience and scientific expertise within the biotechnology and pharmaceutical industries to Odyssey.

TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors. Both bring extensive careers in the strategic, financial and corporate development aspects of building leading biotechnology companies. Together, they will contribute to TOLREMO’s further growth and operational execution as the company advances its lead candidate, TT125-802, designed to prevent transcriptional cancer drug ...

Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors. Both bring deep entrepreneurial and drug development track records that will guide Nimble as it continues to pursue its internal pipeline.

Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, announced expansion of its leadership team with three key industry veterans: Jason Burdette joining as Senior Vice President, CMC and Technical Operations: Armand Girard as Chief Business Officer; and Tamra Adams, and Chief Financial Officer. These appointments come ...

RAPT Therapeutics, Inc., a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations.

NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president, leading the organization into its promising future phase. The appointment comes at a significant time for NMDP, which underwent a unifying, organization-wide brand change earlier this year driven by its expanding global presence, industry-leading research and innovations in cell therapies, such as those led by NMDP BioTherapies.

Immunome, Inc., a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Roberts as Chief Technical Officer. Mr. Roberts has over three decades of experience in product development, global manufacturing, and commercialization of novel pharmaceutical products.

Pacira BioSciences, Inc., the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the “Board”) has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. 

Related Sciences, a leading data science-driven drug discovery firm, today announced the appointment of 8 leading biopharma executives as senior advisors to support its growing portfolio of drug programs, data science capabilities, and R&D partnerships. “We are thrilled to have assembled such a luminary group of senior pharma and biotech executives to support our leadership team as we continue to grow ...

Satellos Bioscience Inc., a publicly traded biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the following updates: AAK1 is the drug target of the Company’s lead drug program in Duchenne muscular dystrophy (“Duchenne” or “DMD”); IND-enabling studies and GMP manufacturing are ongoing; SAT-3247 has been nominated as its lead ...

 Holmusk, a leading global behavioral health real-world evidence company, today announced that it has appointed Eze Abosi as Chief Growth Officer, leading the organization’s commercial team. Eze has nearly two decades of experience leading commercialization of data, analytics and consulting solutions supporting the life sciences and biopharma industries. He joins Holmusk after serving as the Vice President of New Products and Partnership ...

I2Pure announced the hiring of its new Chief Executive Officer, Jeffrey Jochims, effective November 1, 2023. Jeff succeeds I2Pure Founder Douglas Spitz, who is transitioning to the role of Executive Chair. Jochims also joins the I2Pure Board of Directors.

Pacira BioSciences, Inc., the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointments of Marcelo Bigal, MD, PhD, Abraham Ceesay, Michael Yang, and Alethia Young, to its Board of Directors effective immediately. “We are pleased to welcome these four highly seasoned executives to our Board of Directors, whose experience will enhance our ...

Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the appointment of Mark Plavsic, Ph.D., as Chief Technology Officer.

Ontada®, a McKesson business dedicated to leveraging oncology real-world data and evidence, clinical education, and provider technology, announced the appointment of Christine Davis as its new president. In this role, Davis will focus on growing the business and fostering innovation, all to improve the lives of patients and win the fight against cancer. With more than 25 years of experience in the ...

Tourmaline Bio, Inc., a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune diseases, today announced the appointment of Gerhard Hagn, PharmD, to the newly created role of SVP, Head of Commercial and Business Development. In this role, Mr. Hagn will oversee commercial and business development strategy and planning.

Validic, a market-leading digital health and personalized care company, welcomed Jeff Cutler as chief commercial officer. In this role, Cutler will oversee Validic’s strategic approach to generating revenue across its portfolio of SaaS software solutions and services, owning its revenue model, go-to-market approach, and client experience leading sales, marketing, business development and client success.

Aeglea BioTherapeutics, Inc., a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (“IBD”), today announced the appointment of Scott Burrows, as Chief Financial Officer and Heidy Abreu King-Jones as Chief Legal Officer and Corporate Secretary.

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the appointment of Dieter Weinand as Independent Chairman of its Board of Directors. Mr. Weinand brings with him a wealth of experience with more than 35 years in the pharmaceutical industry and over 25 years as the leader of geographic and strategic business units ...

Apogee Therapeutics, Inc., a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease and other inflammatory and immunology (I&I) indications, today announced the appointment of Mark C. McKenna as Chairman of its board of directors. Mr. McKenna’s knowledge and successful track record in the I&I space as well as his significant development, ...

Wellinks, the leading digital healthcare company offering virtual cardiopulmonary disease management for health plans and value-based care providers, today announced Stacie Bratcher as its new Chief Executive Officer.

Apogee Therapeutics, a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease and related inflammatory and immunology indications, today announced the appointments of Jennifer Fox and William “BJ” Jones, seasoned executives in the biotechnology industry, to its board of directors. Ms. Fox will also serve as chair of the company’s audit committee.

1859, an AI-based small molecule drug discovery company advancing next generation medicines, is pleased to announce the appointment of Sanket Agrawal as its Chief Executive Officer (CEO), effective April 2023. As an experienced biopharma business leader, Agrawal joins 1859 to drive its next stage of growth and deliver on the company’s potential to rapidly discover superior molecules. The company has ...

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Marc Besman Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance. Dr. Besman will be responsible for developing, implementing, and advancing global regulatory strategies for Kronos Bio’s portfolio. He will also ensure that the Company upholds the highest ...

Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment of Thaminda Ramanayake as Chief Business Officer. Mr. Ramanayake is a business development and transactions specialist who has spent over a decade working to bring value to patients globally and has a strong track record in company creation, in/out-licensing, ...

AlloVir, a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Cintia Piccina, PharmD, MBA, as the company’s Chief Commercial Officer, effective June 12, 2023. Ms. Piccina will drive the global commercialization strategy for AlloVir, with a focus on its lead product, posoleucel, and be responsible for building a commercial team in anticipation of a 2025 launch.

Impel Pharmaceuticals, a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023.

Cognition Therapeutics, Inc., today announced the appointment of John Doyle to the role of Chief Financial Officer. Mr. Doyle has substantial experience leading and managing financial operations at development- and commercial-stage public life sciences companies through financings, mergers, acquisitions and licensing agreements.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023.

Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors. 

Shyra Gardai, Ph.D., joins as Chief Scientific Officer

Swift Medical appoints health tech industry leader Brian Litten as new CEO

“We are pleased to welcome Tom Heyman to our Board of Directors, “ said Christopher J. Burns, President and Chief Executive Officer. “As a highly respected and seasoned executive and board member, Tom brings a diverse breadth of industry experience across multiple disciplines that will benefit Venatorx as we continue to progress our pipeline of novel anti-infective therapies.

Dr. Avanzi is an experienced physician-scientist and hematologist/oncologist with over fifteen years of clinical experience, including over ten years of experience advancing cellular therapies through early and late-stage of development.  In his new role, Dr. Avanzi will be responsible for leading and expanding Shoreline’s clinical portfolio and will serve as a key member of its Executive team.

Elektrofi strengthens leadership team with appointments of Greg DeFilippis as Chief Business Officer and Paulette Gangemi as Chief Human Resources Officer

Viridian appoints Scott Myers as President and Chief Executive Officer

“Jane is a highly accomplished leader and multiple time CFO with significant expertise in corporate strategy and finance in the healthcare sector, and we are excited to welcome her to our leadership team,” said Michael Henderson, M.D., CEO of Apogee Therapeutics. “Her unique combination of experience as a seasoned biopharmaceutical executive and investment banker will help propel Apogee forward in its ...

Danforth Advisors names Mark E. Spring Managing Director of San Diego Operations, accelerating growth on West Coast

Curve Health names Healthcare Veteran Matthew A. Michela as CEO to expand reach of senior care platform.